Epzicom (abacavir sulfate and lamivudine)
Title: Epzicom (abacavir sulfate and lamivudine)Category: MedicationsCreated: 8/18/2021 12:00:00 AMLast Editorial Review: 8/18/2021 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - August 18, 2021 Category: Infectious Diseases Source Type: news
abacavir, Ziagen
Title: abacavir, ZiagenCategory: MedicationsCreated: 2/24/2001 12:00:00 AMLast Editorial Review: 8/26/2019 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - August 26, 2019 Category: Infectious Diseases Source Type: news
Epzicom (Abacavir Sulfate and Lamivudine Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 11, 2018 Category: Drugs & Pharmacology Source Type: news
Trizivir (Abacavir Sulfate, Lamivudine, and Zidovudine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 3, 2017 Category: Drugs & Pharmacology Source Type: news
Ziagen (Abacavir Sulfate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 31, 2017 Category: Drugs & Pharmacology Source Type: news
Aurobindo Pharma gets USFDA nod for HIV drug
"The company has received final approval from the USFDA to manufacture abacavir sulfate and lamivudine tablets, 600 mg/ 300 mg." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 30, 2017 Category: Pharmaceuticals Source Type: news
abacavir, Ziagen
Title: abacavir, ZiagenCategory: MedicationsCreated: 2/24/2001 12:00:00 AMLast Editorial Review: 6/10/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 10, 2015 Category: Drugs & Pharmacology Source Type: news
FDA Updates Abacavir and Lamivudine Labeling
"On March 23, 2015, FDA approved revisions to the Epivir (lamivudine) and Ziagen (abacavir sulfate) labels to each provide for once-daily dosing in pediatric patients 3 months of age and older in combination with other antiretroviral agents for the treatment of HIV-1 infection."
The updated labeling for both drugs will be available soon at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on abacavir
AIDSinfo: Patient fact sheet on lamivudine (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A S...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - March 27, 2015 Category: Infectious Diseases Source Type: news
FDA Approves New Fixed-Dose Combination Drug, Triumeq (Abacavir Sulfate/Dolutegravir/Lamivudine), to Treat HIV Infection
"On August 22, 2014, FDA approved a new fixed-dose combination product: TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor), abacavir sulfate and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) for the treatment of HIV-1 infection.
"TRIUMEQ alone is not recommended for use in patients with current or past history of resistance to any components of TRIUMEQ.
"TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolut...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news
